Vaccine immunogenicity assays are needed to assess the safety and efficacy of the candidate vaccine, by measuring humoral and cellular immune responses, in an effort to correlate with immunity.
At Viracor we develop and perform a variety of molecular assays for virus detection, and other assays for characterizing the humoral and cellular immune response, as part of clinical studies for our clients and their vaccine candidates.
Eurofins Viracor BioPharma partners with Moderna, performing essential clinical trial testing for COVID-19 Vaccine (click to read the full article)
View Moderna Vaccine Case Study
And learn about Eurofins Viracor's expertise with Immunogenicity Assay Development, Validation & Transfer, for use in vaccine candidate clinical trials, as detailed in this case study (click below).
View Immunogenicity Case Study